Vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) announced on Monday that it has secured its second approval for IXCHIQ, its single-dose chikungunya vaccine.
Health Canada authorised IXCHIQ for preventing chikungunya in adults aged 18 and older.
Chikungunya virus (CHIKV) is a mosquito-borne viral disease spread by the bites of infected female Aedes mosquitoes which causes fever, severe joint pain, muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist for weeks to years.
This decision follows approval by the US Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) is expected to decide on marketing authorisation in Q3 2024.
IXCHIQ, the world's first licensed chikungunya vaccine, targets a significant unmet medical need. Valneva has already begun commercialisation in the United States and targets first Canadian doses by Q4 2024.
Partnerships with CEPI and Instituto Butantan aim to make the vaccine accessible in low- and middle-income countries.
Perrigo announces quarterly dividend
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
CVS Health announces quarterly dividend
Emmaus Life Sciences reports 2023 financial results
Quest Diagnostics to acquire LifeLabs from OMERS for USD1.35bn
Eli Lilly announces Q3 2024 dividend
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
AbbVie announces quarterly cash dividend
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline